Equities Analysts Offer Predictions for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Markets lowered their FY2027 EPS estimates for shares of Intellia Therapeutics in a research note issued on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn $0.92 per share for the year, down from their prior forecast of $0.97. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.21) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ FY2028 earnings at $5.15 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The company had revenue of $7.16 million for the quarter, compared to the consensus estimate of $9.74 million. During the same quarter in the previous year, the firm posted ($0.92) EPS. The business’s revenue for the quarter was down 47.8% compared to the same quarter last year.

A number of other research firms also recently weighed in on NTLA. Citizens Jmp reissued a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Evercore raised Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. Wall Street Zen cut Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $21.44.

Intellia Therapeutics Stock Up 6.7%

Shares of NTLA opened at $12.11 on Monday. The company has a 50-day simple moving average of $12.08 and a 200-day simple moving average of $13.04. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $18.48.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NTLA. BlackRock Inc. bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at approximately $260,721,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Intellia Therapeutics by 24.4% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,605,623 shares of the company’s stock worth $43,484,000 after buying an additional 708,094 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Intellia Therapeutics by 20.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock worth $29,709,000 after buying an additional 386,261 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Intellia Therapeutics in the 1st quarter valued at $17,913,000. Finally, Bank of America Corp DE boosted its stake in Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after buying an additional 139,325 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO John M. Leonard sold 9,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer owned 1,138,064 shares of the company’s stock, valued at $13,645,387.36. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.50% of the stock is currently owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA.

Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.